InvestorsHub Logo
Followers 8
Posts 628
Boards Moderated 0
Alias Born 05/26/2021

Re: None

Wednesday, 10/27/2021 1:19:20 PM

Wednesday, October 27, 2021 1:19:20 PM

Post# of 13742
[{“Subsequent to the acknowledgement of the trial, the FDA has requested that the Company complete two additional toxicology studies in animals. Since adoption of COVID-19 vaccinations, the FDA altered its protocol for measuring toxicology to include studying it at the DNA level. As this is a newer development, the agency has asked Medolife to provide data in this regard. Medolife has the product and protocol necessary to complete these studies in short-order.

“We could not be more pleased with the response from the FDA, in its acknowledgment of our clinical trials on Escozine and its potential therapeutic benefit, as well as the very clear guidelines set forth in the response for moving our program forward,” said Medolife CEO Dr. Arthur Mikaelian.

The acknowledgment by the FDA of the clinical trial conducted in the DR as a proof-of-concept for Escozine®’s therapeutic potential as a COVID-19 therapeutic is an important aspect of the response.]}

http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210623:nGNEb85TRd&default-theme=true

QNTA MedolifeRx AELIA $cience Escozine

https://aeliastore.com/

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.